Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. Return on Capital Employed (ROCE)
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Capital Employed (ROCE) | (123.3%) | (143.6%) | (74.2%) | (35.9%) | (35.4%) | (68.6%) | (32.6%) | (41.8%) | (49.0%) | (33.8%) |
Protagonist Therapeutics, Inc. (PTGX) Return on Capital Employed (ROCE) comparison analysis
PTGX key stats
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
investors
worldwide
FAQ
1) What is Protagonist Therapeutics, Inc.'s Return on Capital Employed (ROCE)?
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is 26.7%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Capital Employed (ROCE) for Protagonist Therapeutics, Inc. have been (27.8%) over the past three years, and (37.0%) over the past five years.
2) Is Protagonist Therapeutics, Inc.'s Return on Capital Employed (ROCE) Good?
As of today, Protagonist Therapeutics, Inc.'s Return on Capital Employed (ROCE) is 26.7%, which is higher than industry median of (51.0%). It indicates that Protagonist Therapeutics, Inc.'s Return on Capital Employed (ROCE) is Good.